Cannabidiol, popularly known as CBD, is a drug that is illegal in a lot of countries and has little or no redeeming value. It is largely known as a vital prescription in the treatment of epilepsy and has some potential in treating other ailments. CBD is a nutraceutical or a dietary supplement that, is natural and it has innumerable evangelists in the wellness and health community.
These statements may be contradictory in a sense but they are all true. These contractions have been a source of great frustration for researchers as they seek to accurately glean the truth from different perspectives.
Several types of research have indicated that CBD is a substance that is safe and is in no way habit-forming. They further show that it does not give the “high” that is common in tetrahydrocannabinol popularly known as THC.
STUCK BETWEEN THE WEEDS
The Food and Drugs Administration in the US concluded in 2018 that a CBD product helps to effectively reduce seizure frequencies. This conclusion came from the discovery of its impact, especially in rare stages of pediatric epilepsy.
The approval of this product came about from the strong advocacy that came from families with children at various stages of epilepsy.
Several types of research that were conducted in the 1970s and 1980s on CBD looked into its interplay alongside several other cannabinoids with emphasis on THC. The conclusions showed that THC impairs cognition, introduces anxiety, and psychotic symptoms. They further discovered that the effect of CBD is opposite to that of THC.
However, cannabidiol has various aspects. It looks like it facilitates its antiepileptic impact by fusing with a protein that is commonly known as GPR55. This can cause various triggering of seizures through the promotion of hyper-activation of the neurons. Berkshirecbd experts shed more light on this.
Secondly, cannabidiol affects receptors that facilitate inflammation and pain signaling. including the minimum of one neurotransmitter serotonin receptor. This implies that the psychological effects of CBD are similar to that of selective serotonin reuptake inhibitor drugs known as SSRI. These drugs are usually used in the treatment of clinical depression.
The proven medicinal advantages of cannabidiol are minimal outside epilepsy. This is because of the inconsistent and small-scale trial design. However, interesting progress is being made when it comes to treating other ailments. When looking at the schizophrenic context, Psychosis is one of the areas where CBD is showing exciting progress.
A report in 1995 showed that a patient with schizophrenia experienced considerable relief from its symptoms when treated with high doses of cannabidiol. Other small-scale clinical research has identified similar hints of efficiency.
A ground-breaking experiment that was conducted on CBD and amisulpride indicated a considerable decrease in symptoms over time for both compounds. However, the conclusion of the experiment was that amisulpride was by far beaten by CBD when it comes to side effects.
The team that conducted the experiment discovered the mechanism that they believed by which cannabidiol carries out its anti-psychotic effects. This mechanism showed an increase in anandamide levels. Anandamide is a cannabinoid that is manufactured by the body to protect it from psychosis.
Cannabidiol has also shown to help in alleviating anxiety disorders among other mental health conditions.